Navigation Links
Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Date:9/17/2009

ied by such statements. There can be no guarantee that Valturna will be approved for sale in any additional markets. Nor can there be any guarantee that Tekturna will be approved for any additional indications or labeling in any market. Neither can there be any guarantee that Valturna, Tekturna or Diovan will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatolo
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
2. Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension
3. Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation
4. J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards
5. Novartis Oncology Launches GIST Alliance™ for Patients and Caregivers
6. Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors
7. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
8. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
9. Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
10. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
11. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Cary, N.C. (PRWEB) October 30, 2014 ... consumer-driven health care, is increasing efforts to help people ... out-of-pocket expenses continue to increase for prescription drugs in ... provides valuable savings and resources to bridge the relationship ... , One of the biggest challenges people face today ...
(Date:10/30/2014)... October 30, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... brain health. , The study, performed by the University ... 60 and 78 over a week-long period and observed ... daily physical activity. By examining the structural soundness of ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... -- When it comes to heart disease, a new study ... when they have symptoms that spell trouble. "The main ... a more severe or advanced stage of heart disease, there ... a Fulbright Scholar and research fellow at the Harvard School ... Heart and Stroke Foundation of Canada. In the study, ...
(Date:10/30/2014)... -- Eating a low-carb, high-fat diet could help control ... research. A review of five studies found ... on foods like bacon, eggs, heavy cream, butter, fish ... whose condition doesn,t improve with medication. "We need ... epilepsy whose seizures are not stopped by medications," study ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... S.C., June 2 Companion Data Services, ... International Organization for,Standardization (ISO) 9001:2000 certification, the ... CDS provides information technology and data processing ... by the federal,Centers for Medicare & Medicaid ...
... Work, Discusses Abbott,s, Contributions to Access, Innovation, Science ... June 2 Abbott (NYSE: ABT ),today ... Work,",which is available online at http://www.abbott.com/citizenship . ... innovation, science,education and the environment., Named to ...
... problem of how many identical-sized spheres can be randomly ... A team of physicists at The City College ... solution that could have implications for everything from processing ... May 29 edition of "Nature," they demonstrate that random ...
... Ignoring scientific,evidence of harm, the Louisiana State ... by the House, will require fluoride chemicals be,added ... to reduce,tooth decay. (The Advocate, 5/29/08), However, ... by,the prestigious National Research Council (NRC) reveals that ...
... Way for Approval of Merger, CHICAGO, June ... connectivity and information solutions that,physicians use to improve ... Hart-Scott-Rodino (HSR) Antitrust Improvements Act of,1976, with respect ... 2008,between Allscripts and Misys Healthcare to form Allscripts-Misys ...
... 15% of their daily calories, study finds , , MONDAY, June ... more sugary beverages and fruit juices than ever before, a ... now take in up to 15 percent of their total ... confirms previous research and suggests consumption is rising. , It,s ...
Cached Medicine News:Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 2Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 3Health News:Louisiana May Mandate Fluoridation Despite Evidence of Harm 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Kids Gulping Down More Sugary Beverages 2Health News:Kids Gulping Down More Sugary Beverages 3
(Date:10/30/2014)...  The number of retail health clinics in ... thanks to drug store chains, according to Kalorama Information.  ... downturn, retail clinic growth had been at a standstill, ... number of retail clinics reached nearly 1,600 according to ... Overview and 2014 Consumer Survey Results .  ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
(Date:10/30/2014)... , October 30, 2014 ... GG hilft beim Aufbau von Kuhmilchverträglichkeit     ... für Lebensmittelallergien bei Säuglingen und Kleinkindern. Der ... bei der Ernährung der Babys bzw. deren ... sich jedoch, dass sich bei einer beträchtlichen ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3
... Inc. (Nasdaq: REGN ) today announced that ... the U.S. Food and Drug Administration (FDA) for VEGF ... age-related macular degeneration (wet AMD).  Under the Prescription Drug ... review time from submission to FDA action is ten ...
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
Cached Medicine Technology:Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 2Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 3Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 4Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 5Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 6Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration 7ResearchDx Launches Contract Diagnostics Organization (CDO) 2
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
... This remarkable anti-reflux valve is ... housing which prevents the valve ... when in sitting or reclining ... self-cleaning and interference free ensuring ...
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter is 8 inches (20.3 cm) in length and features a male luer on the single leg. A soft "Y" terminates in two 1/4 inches (0.64 cm) slip connectors, one with a vent....
Medicine Products: